3634 J ournal of Medicinal Chemistry, 1998, Vol. 41, No. 19
Spadoni et al.
B.; Delagrange, P.; Guardiola, B.; Yous, S.; Demarque, A.; Adam,
G.; Andrieux, J . Synthesis and structure-activity relationships
of novel naphthalenic and bioisosteric related amidic derivatives
as melatonin receptor ligands. J . Med. Chem. 1994, 37, 3231-
3239. (e) Langlois, M.; Bre´mont, B.; Shen, S.; Poncet, A.;
Andrieux, J .; Sicsic, S.; Serraz, I.; Mathe´-Allainmat, M.; Renard,
P.; Delagrange, P. Design and synthesis of new naphthalenic
derivatives as ligands for 2-[125I]Iodomelatonin binding sites. J .
Med. Chem. 1995, 38, 2050-2060. (f) Copinga, S.; Tepper, P.
G.; Grol, C. J .; Horn, A. S.; Dubocovich, M. L. 2-Amido-8-
methoxytetralins: A series of nonindolic melatonin-like agents.
J . Med. Chem. 1993, 36, 2891-2898. (g) Garratt, P. J .; Vonhoff,
S.; Rowe, S. J .; Sugden, D. Mapping the melatonin receptor. 2.
Synthesis and biological activity of indole derived melatonin
analogues with restricted conformations of the C-3 amidoethane
side chain. Bioorg. Med. Chem. Lett. 1994, 4, 1559-1564.
(22) (a) Spadoni, G.; Balsamini, C.; Diamantini, G.; Di Giacomo, B.;
Tarzia, G.; Mor, M.; Plazzi, P. V.; Rivara, S.; Lucini, V.; Nonno,
R.; Pannacci, M.; Fraschini, F.; Stankov, B. M. Conformationally
restrained melatonin analogues: synthesis, binding affinity for
the melatonin receptor, evaluation of the biological activity and
molecular modeling study. J . Med. Chem. 1997, 40, 1990-2002.
(b) J ansen, J . M.; Copinga, S.; Gruppen, G.; Molinari, E. J .;
Dubocovich, M. L.; Grol, C. J . The high affinity melatonin
binding site probed with conformationally restricted ligands-I.
Pharmacophore and minireceptor models. Bioorg. Med. Chem.
1996, 4, 1321-1332. (c) Grol, C. J .; J ansen, J . M. The high
affinity melatonin binding site probed with conformationally
restricted ligands-II. Homology modeling of the receptor. Bioorg.
Med. Chem. 1996, 4, 1333-1339. (d) Sugden, D.; Chong, N. W.
S.; Lewis, D. F. V. Structural requirements at the melatonin
receptor. Br. J . Pharmacol. 1995, 114, 618-623. (e) Sicsic, S.;
Serraz, I.; Andrieux, J .; Bre´mont, B.; Mathe´-Allainmat, M.;
Poncet, A.; Shen, S.; Langlois, M. Three-dimensional quantita-
tive structure-activity relationship of melatonin receptor
ligands: a comparative molecular field analysis study. J . Med.
Chem. 1997, 40, 739-748. (f) Navajas, C.; Kokkola, T.; Poso,
A.; Honka, N.; Gynther, J .; Laitinen, J . T. A rhodopsin-based
model for melatonin recognition at its G protein-coupled receptor.
Eur. J . Pharmacol. 1996, 304, 173-183.
tion of the human melatonin Mel1a receptor following stable
transfection into NIH3T3 cells. Br. J . Pharmacol. 1998, 124,
485-492.
(33) It had been previously suggested that the 5-methoxy group, or
the equivalent positional isomer, is an essential requirement for
melatonin intrinsic activity,34,21f but this suggestion was recently
questioned.35
(34) (a) Heward, C. B.; Hadley, M. E. Structure-activity relations
of melatonin and related indolamines. Life Sci. 1975, 17, 1167-
1177. (b) Dubocovich, M. L. Characterization of
a retinal
melatonin receptor. J . Pharmacol. Exp. Ther. 1985, 234, 395-
401.
(35) Garratt, P. J .; J ones, R.; Rowe, S. J .; Sugden, D. Mapping the
melatonin receptor. 1. The 5-methoxyl group of melatonin is not
an essential requirement for biological activity. Bioorg. Med.
Chem. Lett. 1994, 4, 1555-1558.
(36) Allen, M. S.; Hamaker, L. K.; La Loggia, A. J .; Cook, J . M. Entry
into 6-methoxy-D(+)-tryptophans. Stereospecific synthesis of
1-benzenesulfonyl-6-methoxy-D(+)-tryptophan ethyl ester. Synth.
Commun. 1992, 22, 2077-2102.
(37) (a) Fanta, P. E. The Ullmann Synthesis of biaryls. Synthesis
1974, 9-21. (b) Perregaard, J .; Moltzen, E. K.; Meier, E.;
Sa´nchez, C. σ Ligands with subnanomolar affinity and prefer-
ence for the σ2 binding site. 1. 3-(ω-Aminoalkyl)-1H-indoles. J .
Med. Chem. 1995, 38, 1998-2008.
(38) Siddappa, S.; Bhat, G. A. Synthesis of indole-2-carboxaldehydes,
2-(2-aminoethyl)- and 2-(2-aminopropyl)indoles. J . Chem. Soc.,
C. 1971, 178-81.
(39) Wittig, G.; Scho¨llkopf, U. Triphenylphosphinemethylene as an
olefin-forming reagent. I. Chem. Ber. 1954, 97, 1318-1330.
(40) Novikov, S. S.; Shvekhgeimer, G. A. Preparation of aromatic
nitro ketones and nitro nitriles by the Wittig reaction. Izvest.
Akad. Nauk S.S.S.R., Otdel. Khim. Nauk 1960, 2061-2063;
Chem. Abstr. 1961, 55, 13353g.
(41) Cheng, Y.-C.; Prusoff, W. H. Relationship between the inhibition
constant (Ki) and the concentration of inhibitor which causes
50% inhibition (I50) of an enzymatic reaction. Biochem. Phar-
macol. 1973, 22, 3099-3108.
(42) Morgan, P. J .; Barrett, P.; Howell, H. E.; Helliwell, R. Melatonin
receptors: localization, molecular pharmacology and physiologi-
cal significance. Neurochem. Int. 1994, 24, 101-146.
(43) Wreggett, K. A.; De Lean, A. The ternary complex model. Its
properties and application to ligand interactions with the D2-
dopamine receptor of the anterior pituitary gland. Mol. Phar-
macol. 1984, 26, 214-227.
(44) Birnbaumer, L.; Abramowitz, J .; Brown, A. M. Receptor-effector
coupling by G-proteins. Biochim. Biophys. Acta 1990, 1031, 163-
224.
(45) (a) Hilf, G.; Gierschik, P.; J akobs, K. H. Muscarinic acetylcholine
receptor-stimulated binding of guanosine 5′-O-(3-thiotriphos-
phate) to guanine nucleotide-binding proteins in cardiac mem-
branes. Eur. J . Biochem. 1989, 186, 725-731. (b) Lorenzen, A.;
Fuss, M.; Vogt, H.; Schwabe, U. Measurement of guanine
nucleotide-binding protein activation by A1 adenosine receptor
agonists in bovine brain membranes: stimulation of guanosine
5′-O-(3-[35S]thio)triphosphate binding. Mol. Pharmacol. 1993, 44,
115-123. (c) Lazareno, S.; Birdsall, N. J . Pharmacological
characterization of acetylcholine-stimulated [35S]GTPγS binding
mediated by human muscarinic m1-m4 receptors: antagonist
studies. Br. J . Pharmacol. 1993, 109, 1120-1127.
(46) Lew, M. J .; Angus, J . A. Analysis of competitive agonist-
antagonist interactions by nonlinear regression. Trends Phar-
macol. Sci. 1995, 16, 328-337.
(47) Kubinyi, H. The Free-Wilson method and its relationship to the
extrathermodynamic approach. In Comprehensive Medicinal
Chemistry; Hansch, C., Sammes, P. G., Taylor, J . B., Eds.;
Pergamon Press: Oxford, U.K., 1990; Vol. 4, pp 589-643.
(48) Draper, N.; Smith, H. Applied Regression Analysis, 2nd ed.;
Wiley: New York, 1981; pp 294-379.
(23) (a) Pickering, H.; Sword, S.; Vonhoff, S.; J ones, R.; Sugden, D.
Analogues of diverse structure are unable to differentiate native
melatonin receptors in the chicken retina, sheep pars tuberalis
and Xenopus Melanophores. Br. J . Pharmacol. 1996, 119, 379-
387. (b) Takaki, K. S.; Mahle, C. D.; Watson, A. J . Melatonergic
ligands: pharmaceutical development and clinical applications.
Curr. Pharm. Des. 1997, 3, 429-438.
(24) Dubocovich, M. L. Luzindole (N-0774):
a novel melatonin
receptor antagonist. J . Pharmacol. Exp. Ther. 1988, 246, 902-
910.
(25) Copinga, S.; Van Brummelen, G.; Drijfhout, W. J .; Tepper, P.
G.; Grol, C. J .; Horn, A. S.; Dubocovich, M. L. Synthesis and
pharmacological evaluation of 4-aryl-2-amidotetralins: nonin-
dolic melatonin-receptor agents. Proceedings of the XIIIth
international symposium on medicinal chemistry, Paris, Sept
19-23, 1994.
(26) Garratt, P. J .; J ones, R.; Tocher, D. A.; Sugden, D. Mapping the
melatonin receptor. 3. Design and synthesis of melatonin ago-
nists and antagonists derived from 2-phenyltryptamines. J . Med.
Chem. 1995, 38, 1132-1139.
(27) Guardiola-Lemaitre, B.; Delagrange, P. Melatonin analogues:
from pharmacology to clinical application. Eur. J . Med. Chem.
1995, 30, 643s-651s.
(28) Dubocovich, M. L.; Masana, M. I.; Iacob, S.; Sauri, D. M.
Melatonin receptor antagonists that differentiate between the
human Mel1a and Mel1b recombinant subtypes are used to assess
the pharmacological profile of the rabbit retina Ml1 presynaptic
heteroreceptor. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1997,
355, 365-375.
(49) Milligan, G.; Bond, R. A.; Lee, M. Inverse agonism: pharmaco-
logical curiosity or potential therapeutic strategy? Trends Phar-
macol. Sci. 1995, 16, 10-13.
(50) Hiremath, S. P.; Purohit, M. G. Synthesis of 3,4-dihydropyrido-
[4,3-b]indoles using polyphosphate ester as a cyclizing agent.
Indian J . Chem. 1972, 10, 984-986.
(29) Dubocovich, M. L. N-Acetyltryptamine antagonizes the melato-
nin-induced inhibition of [3H]dopamine release from retina. Eur.
J . Pharmacol. 1984, 105, 193-194.
(51) Bradford, M. M. A rapid and sensitive method for the quanti-
tation of microgram quantities of protein utilizing the principle
of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
(52) (a) Cozzi, B.; Stankov, B.; Viglietti-Panzica, C.; Capsoni, S.; Aste,
N.; Lucini, V.; Fraschini, F.; Panzica, G. C. Distribution and
characterization of melatonin receptors in the brain of the
J apanese quail, Coturnix japonica. Neurosci. Lett. 1993, 150,
149-152. (b) Stankov, B.; Cozzi, B.; Lucini, V.; Fumagalli, P.;
Scaglione, F.; Fraschini, F. Characterization and mapping of
melatonin receptors in the brain of three mammalian species:
rabbit, horse and sheep. A comparative in vitro binding study.
Neuroendocrinology 1991, 53, 214-221.
(30) This work had been completed when a paper by Davies et al.31
appeared, reporting that the affinity of N-butanoyl and N-pro-
panoyl-10-(aminomethyl)-2-methoxy-5-methyl-5,6,7,8,9,10-hexahy-
drocyclohept[b]indoles for the chicken brain receptor is in the
nanomolar range (Ki ) 10.3 and 6.5 nM) and that some of these
compounds show a good propensity to behave as antagonists.
(31) Davies, D. J .; Garratt, P. J .; Tocher, D. A.; Vonhoff, S.; Davies,
J .; Teh, M. T.; Sugden, D. Mapping the melatonin receptor. 5.
Melatonin agonists and antagonists derived from tetrahydrocy-
clopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept-
[b]indoles. J . Med. Chem. 1998, 41, 451-467.
(32) Nonno, R.; Lucini, V.; Pannacci, M.; Mazzucchelli, C.; Angeloni,
D.; Fraschini, F.; Stankov, B. M. Pharmacological characteriza-
J M970721H